U
GHDX

UBS’s Genomic Health, Inc. GHDX Stock Holding History

UBS’s Portfolio GHDX Stock Details GHDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-1,000
Closed -$29K – 11027
2013
Q4 		$29K Buy
+1,000
New +$31.7K ﹤0.01% 7698
2013
Q3 		– Sell
-4,200
Closed -$133K – 10867
2013
Q2 		$133K Buy
+4,200
New +$138K ﹤0.01% 5550

Other funds holding GHDX

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
NTC
North Tide Capital Boston, Massachusetts $469M AUM 6.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS's GHDX Position: Q2 2014 in Review

UBS sold out of Genomic Health, Inc. (GHDX) in Q2 2014, closing a stake of 2,596 shares — an estimated $69.1K sold.

UBS first reported a position in GHDX in Q2 2013 and held it in 4 quarters. The position peaked at $148K in Q4 2013. 112 funds tracked by Wall St. Rank hold GHDX as of Q2 2014.

  • UBS reported no remaining Genomic Health, Inc. position as of Q2 2014 after selling out during the quarter.
  • UBS sold 2,596 Genomic Health, Inc. shares in Q2 2014, an estimated $69.1K.
  • UBS first reported a position in Genomic Health, Inc. in Q2 2013 and held it in 4 quarters.
  • UBS's Genomic Health, Inc. position peaked at $148K in Q4 2013.
  • 112 funds tracked by Wall St. Rank held Genomic Health, Inc. as of Q2 2014.

Based on UBS's 13F filing for Q2 2014, filed 14 Aug 2014.